4521.T
4521.T
JP3207000005
KAKEN PHARMACEUTICAL
Loading chart...
Solid Quality Asset with Moderate Fluctuation

Healthy balance: Exemplary business financials (Health Score: 85/100) paired with moderate price swings for a single equity (±19.6% p.a.). The score (5/7) reflects the standard baseline for equities under SRI rules.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
5/7 Elevated
5 / 7 SRI Price Fluctuation & Beta

Above-average volatility. Suitable for experienced investors with high risk tolerance (5+ years horizon).

Beta (Market Relation)
-
Defensive
Volatility (5Y p.a.)
19.6% p.a.
5-Year Horizon
Max Drawdown (5Y)
-30.2%
5-Year Horizon
Sharpe Ratio
-0.32
Return / Risk
Elevated Risk / Growth: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -1.1%
3 Years 20.8% -25.8% -0.01 +2.2%
5 Years 19.6% -30.2% -0.32 -3.8%
10 Years 22.2% -54.1% -0.35 -5.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 65.7 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Historical Stress Test: Maximum peak-to-trough drawdown of -54.1% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
7 ISS Score: 7 / 10
Audit Risk
1 ISS Score: 1 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
-
ende